Cited by 1,879Chemical Synthesis and AnalysisNeuropeptides and Animal PhysiologyMicrobial Natural Products and Biosynthesis

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Therapeutic peptides: Historical perspectives, current development trends, and future directions

Open access

Lau, Jolene L., Dunn, Michael K.·2018·Bioorganic & Medicinal Chemistry

DOI 10.1016/j.bmc.2017.06.052

Open this paper in CoChat — free account Open PDF

Abstract

Peptide therapeutics have played a notable role in medical practice since the advent of insulin therapy in the 1920s. Over 60 peptide drugs are approved in the United States and other major markets, and peptides continue to enter clinical development at a steady pace. Peptide drug discovery has diversified beyond its traditional focus on endogenous human peptides to include a broader range of structures identified from other natural sources or through medicinal chemistry efforts. We maintain a comprehensive dataset on peptides that have entered human clinical studies that includes over 150 peptides in active development today. Here we provide an overview of the peptide therapeutic landscape, including historical perspectives, molecular characteristics, regulatory benchmarks, and a therapeutic area breakdown.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.bmc.2017.06.052

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A new antibiotic kills pathogens without detectable resistance
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., Müller, A., Schäberle, T. F., Hughes, D. E., Epstein, S. S., et al. (2015) · Nature · doi:10.1038/nature14098 · Cited by 2,428
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
Advances in Fmoc solid‐phase peptide synthesis
Behrendt, R., White, P., & Offer, J. (2016) · Journal of Peptide Science · doi:10.1002/psc.2836 · Cited by 767
Untitled work
(1922) · PubMed · Cited by 753
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
Chang, Y. S., Graves, B. J., Guerlavais, V., Tovar, C., Packman, K. E., To, K.-H., Olson, K. A., Kesavan, K. P., Gangurde, P., Mukherjee, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303002110 · Cited by 681
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
Large-scale manufacture of peptide therapeutics by chemical synthesis
Bray, B. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1133 · Cited by 601
Asprosin, a Fasting-Induced Glucogenic Protein Hormone
Romere, C., Duerrschmid, C., Bournat, J., Constable, P., Jain, M., Xia, F., Saha, P. K., Del Solar, M., Zhu, B., York, B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.063 · Cited by 591
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
Bussel, J. B., Kuter, D. J., George, J. N., McMillan, R., Aledort, L. M., Conklin, G. T., Lichtin, A. E., Lyons, R. M., Nieva, J. J., Wasser, J. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054626 · Cited by 525
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 491
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
Kühnen, P., Clément, K., Wiegand, S., Blankenstein, O., Gottesdiener, K., Martini, L. L., Mai, K., Blume-Peytavi, U., Grüters, A., & Krude, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512693 · Cited by 485
The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin
Birk, A. V., Liu, S., Soong, Y., Mills, W., Singh, P., Warren, J. D., Seshan, S. V., Pardee, J. D., & Szeto, H. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012121216 · Cited by 479
Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial
Hill, M. D., Martin, R., Mikulis, D. J., Wong, J. H., Silver, F. L., terBrugge, K. G., Milot, G., Clark, W. M., Macdonald, R. L., Kelly, M., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70225-9 · Cited by 403
Pancreatic Extracts in The Treatment of Diabetes Mellitus
Banting, F., BEST, C. H., Collip, J. B., Campbell, W. R., & Fletcher, A. A. (1956) · Diabetes · doi:10.2337/diab.5.1.69 · Cited by 347
A Novel Ligand of the Formyl Peptide Receptor
Walther, A., Riehemann, K., & Gerke, V. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80323-8 · Cited by 322
Gut-Brain Cross-Talk in Metabolic Control
Clemmensen, C., Müller, T. D., Woods, S. C., Berthoud, H., Seeley, R. J., & Tschöp, M. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.025 · Cited by 309
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Insights into the structure of class B GPCRs
Hollenstein, K., de Graaf, C., Bortolato, A., Wang, M., Marshall, F. H., & Stevens, R. C. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.001 · Cited by 240
Clinical Approval Success Rates for Investigational Cancer Drugs
DiMasi, J. A., Reichert, J. M., Feldman, L., & Malins, A. J. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.117 · Cited by 206
Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
Melmed, S. K., POPOVIC, V. M., Bidlingmaier, M., Mercado, M., van der Lely, A. J., Biermasz, N. R., Bolanowski, M., Coculescu, M., Schopohl, J., Rácz, K., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4113 · Cited by 173
Strategies To Deliver Peptide Drugs to the Brain
Lalatsa, A., Schätzlein, A. G., & Uchegbu, I. F. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400680d · Cited by 167
Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man.
Hollenberg, N. K., Williams, G. H., Burger, B. M., Ishikawa, I., & Adams, D. F. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108266 · Cited by 163
Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy
Abbara, A., Jayasena, C. N., Christopoulos, G., Narayanaswamy, S., Izzi‐Engbeaya, C. N., Nijher, G. M. K., Comninos, A. N., Peters, D., Buckley, A. J., Ratnasabapathy, R., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2332 · Cited by 153
Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models
Peng, S.-B., Zhang, X., Paul, D. C., Kays, L. M., Gough, W. H., Stewart, J. A., Uhlik, M. T., Chen, Q., Hui, Y., Zamek‐Gliszczynski, M. J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0850 · Cited by 149
EFFECTS OF PITUITARY ADRENOCORTICOTROPIC HORMONE (ACTH) THERAPY
ELKINTON, J. R. (1949) · JAMA · doi:10.1001/jama.1949.02910180001001 · Cited by 142
Chemical Engineering News
MURPHY, W. J. (1951) · Chemical & Engineering News · doi:10.1021/cen-v029n014.p1289 · Cited by 131
Drug Design at Peptide Receptors
Hannon, J. P., Nunn, C., Stolz, B., Bruns, C., Weckbecker, G., Lewis, I., Troxler, T. J., Hurth, K., & Hoyer, D. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:15 · Cited by 119
Optimized deep-targeted proteotranscriptomic profiling reveals unexplored Conus toxin diversity and novel cysteine frameworks
Lavergne, V., Harliwong, I., Jones, A., Miller, D. K., Taft, R. J., & Alewood, P. F. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501334112 · Cited by 93
Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists
Mishra, R. K., Shum, A. K., Platanias, L. C., Miller, R. J., & Schiltz, G. E. (2016) · Scientific Reports · doi:10.1038/srep30155 · Cited by 74
Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye
Meerovitch, K., Torkildsen, G. L., Lonsdale, J. D., Goldfarb, H. B., Lama, T., Cumberlidge, G., & Ousler, G. W. (2013) · Clinical ophthalmology · doi:10.2147/opth.s44688 · Cited by 73
Oral delivery of peptides: opportunities and issues for translation
Brayden, D. J., & Alonso, M. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.10.005 · Cited by 62
Cardiovascular effects of a PEGylated apelin
Jia, Z. Q., Hou, L., Leger, A., Wu, I., Kudej, A. B., Stefano, J. E., Jiang, C., Pan, C. Q., & Akita, G. Y. (2012) · Peptides · doi:10.1016/j.peptides.2012.09.003 · Cited by 55
Current trends in the clinical development of peptide therapeutics.
Saladin, P. M., Zhang, B. D., & Reichert, J. M. (2009) · PubMed · Cited by 48
Intestinal absorption of the octapeptide SMS 201–995 visualized by fluorescence derivatization
Fricker, G., Bruns, C., Munzer, J., Briner, U., Albert, R., Kissel, T., & Vonderscher, J. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90651-z · Cited by 45
MAKING PEPTIDES AT LARGE SCALE
Thayer, A. M. (2011) · Chemical & Engineering News · doi:10.1021/cen-v089n022.p021 · Cited by 45
Opportunistic Sampling of Roadkill as an Entry Point to Accessing Natural Products Assembled by Bacteria Associated with Non-anthropoidal Mammalian Microbiomes
Motley, J. L., Stamps, B. W., Mitchell, C. A., Thompson, A. T., Cross, J., You, J., Powell, D. R., Stevenson, B. S., & Cichewicz, R. H. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6b00772 · Cited by 30
Synthetic non‐peptide low molecular weight agonists of the relaxin receptor 1
Agoulnik, A. I., Agoulnik, I. U., Hu, X., & Marugán, J. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13656 · Cited by 28
Adrenomedullin 2.0: Adjusting Key Levers for Metabolic Stability
Schönauer, R. A.-R., Els‐Heindl, S., Fischer, J., Köbberling, J., Riedl, B., & Beck‐Sickinger, A. G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00126 · Cited by 26
The design and implementation of a generic lipopeptide scanning platform to enable the identification of ‘locally acting’ agonists for the apelin receptor
McKeown, S. C., Zécri, F. J., Fortier, E., Taggart, A. K. P., Sviridenko, L., Adams, C. M., McAllister, K., & Pin, S. S. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.08.045 · Cited by 18
PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration
Masuda, Y., Kumano, S., Noguchi, J., Sakamoto, K., Inooka, H., & Ohtaki, T. (2017) · Peptides · doi:10.1016/j.peptides.2017.04.001 · Cited by 16
Once-yearly device takes on daily and weekly diabetes drugs
Mullard, A. (2014) · Nature Biotechnology · doi:10.1038/nbt1214-1178 · Cited by 7

Flagged first, then by citations

1 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 2,074
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes
Kumari, S., Carmona, A. V., Tiwari, A. K., & Trippier, P. C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00530 · Cited by 692

See all 1,879

Authors: Lau, J. L., & Dunn, M. K.
Affiliations: Ferring Research Institute (United States) (US)
Corresponding author: Dunn, Michael K.
Venue: Bioorganic & Medicinal Chemistry
Publisher: Elsevier BV
Published: 2018-06
Volume: 26
Issue: 10
Pages: 2700-2707
ISSN: 0968-0896 (ISSN-L)
DOI: 10.1016/j.bmc.2017.06.052
OpenAlex: W2724823461
Cited by: 1,879
References: 44
Citations by year: 2026: 146 · 2025: 179 · 2024: 205 · 2023: 236 · 2022: 299 · 2021: 275 · 2020: 278 · 2019: 194 · 2018: 59
FWCI: 13.65
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Bioorganic & Medicinal Chemistry (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
Keywords: peptide therapeutics, peptide drug discovery, clinical development, insulin, therapeutic areas
MeSH terms: Animals, Drug Evaluation, Humans, Peptides, Drug Approval, Drug Discovery, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic peptides: Historical perspectives, current development trends, and future directions

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks